Home > Insider Trading > Filing (0000899243-19-013253)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1563880	Trevi Therapeutics Inc.	TRVI	Pharmaceutical Preparations (2834)	450834299

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1722234	Kirstine Mette Agger	C/O Trevi Therapeutics, Inc. 195 Church Street, 14Th Floor New Haven CT 06510		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-05-09	776,544	$0.00	776,544	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2019-05-09	375,000	$10.00	1,151,544	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series C Preferred Stock	Disposition	2019-05-09	6,849,315	$0.00	776,544	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
These shares are directly held by Lundbeckfond Invest A/S. The reporting person is the Managing Partner at Lundbeckfonden Ventures, which is the General Partner of Lundbeckfond Invest A/S. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose.